New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
07:36 EDTDSCIDerma Sciences reports Q2 EPS (34c), consensus (46c)
Reports Q2 revenue $20.9M, consensus $21.47M. “Our AWC business faced headwinds during the second quarter that were specific to the U.S. and were temporary in nature, including reimbursement and competitive pressures. While AWC sales results were below expectations, our franchise continued to grow and I am pleased with how effectively the Derma Sciences team addressed those challenges and how well we are positioned for the future,” said Edward J. Quilty, chairman and CEO.
News For DSCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
10:00 EDTDSCIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:48 EDTDSCIDerma Sciences downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray downgraded Derma Sciences to Neutral citing a lack of growth catalysts with management's "tepid" expectations regarding the growth of the advanced wound care segment in 2015. Piper cut its price target for shares to $9 from $12.
January 22, 2015
09:18 EDTDSCIDerma Sciences' amniotic tissue products incorporated to Premier portfolio
Derma Sciences' (DSCI) Amnioexcel and Amniomatrix , amniotic allografts derived from placental tissues, have been added to the Premier (PINC) Regenerative Skin Grafting contract portfolio.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use